The National Institute for Health and Care Excellence (NICE) has proposed that women with polyendocrine metabolic ovarian syndrome (PMOS) receive annual reviews [1].
This move aims to address the chronic under-diagnosis of the condition and ensure that patients receive consistent monitoring for long-term health risks [1, 3]. By standardizing care, the NHS seeks to improve early diagnosis, and the management of symptoms for a population that has historically been overlooked [1, 3].
According to the draft guidelines, the annual review would focus on monitoring symptoms and assessing the effectiveness of ongoing treatments [1]. The proposal was first announced during a public consultation on May 16, 2026 [4]. The health watchdog said these reviews would help clinicians track the progression of the syndrome and intervene early to prevent further complications [1].
The scale of the condition is significant, though estimates vary by source. NICE said millions of women are affected by PMOS [1], while other reports suggest the number could be as high as tens of millions [5]. This discrepancy highlights the difficulty in tracking the condition due to the very under-diagnosis the new guidelines intend to solve [1].
PMOS, previously referred to as PCOS, involves complex endocrine and metabolic disruptions. The new draft guidelines emphasize that a yearly check-up is necessary to manage the multifaceted nature of the syndrome [1, 4]. These reviews would be integrated into the existing National Health Service (NHS) framework to provide a structured pathway for patient care [1, 2].
The guidelines are currently in the draft stage, allowing for professional and public feedback before they are finalized into official medical practice [1].
“Millions of women are affected by PMOS”
The transition from PCOS to the PMOS designation and the introduction of mandatory annual reviews signal a shift toward recognizing the condition as a systemic metabolic disorder rather than a localized ovarian issue. By institutionalizing yearly checks, the NHS is attempting to move from reactive treatment to a proactive preventative model, potentially reducing long-term comorbidities associated with endocrine dysfunction.
